Latest Articles
High response rates in platinum-resistant ovarian cancer with immunotherapy agents - MSN
High response rates in platinum-resistant ovarian cancer with immunotherapy agents MSN
Published: April 20, 2026, 8:14 a.m.
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer - Pharmacy Times
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer Pharmacy Times
Published: April 17, 2026, 12:30 p.m.
High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents - MedPage Today
High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents MedPage Today
Published: April 16, 2026, 7:11 p.m.
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy TipRanks
Published: April 15, 2026, 1:38 p.m.
Lena Dunham's Chronic Illness Battle - The Pain She Hid While the World Was Busy Hating Her - privatetherapyclinics.co.uk
Lena Dunham's Chronic Illness Battle - The Pain She Hid While the World Was Busy Hating Her privatetherapyclinics.co.uk
Published: April 13, 2026, 9:40 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KELO-AM
GSK sees blockbuster potential in targeted cancer therapy after promising early data KELO-AM
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KFGO
GSK sees blockbuster potential in targeted cancer therapy after promising early data KFGO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WKZO
GSK sees blockbuster potential in targeted cancer therapy after promising early data WKZO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WSAU
GSK sees blockbuster potential in targeted cancer therapy after promising early data WSAU
Published: April 12, 2026, 8:44 p.m.
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive
Published: April 12, 2026, 2:35 p.m.
Link copied to clipboard!